Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, presented detailed results from its V012 Phase 3 study showing that the Company's bioengineered blood vessel – the acellular tissue engineered vessel, or ATEV – outperformed autologous arteriovenous (AV) fistula, the current standard of care, for women on dialysis. The results were presented at a Women's Health seminar during the Society for Vascular Surgery's (SVS's) Vascular Annual Meeting (VAM) in Boston.